Vaccine for preventing or treating congenital infection with cytomegalovirus
A human cytomegalovirus, congenital technology, applied in the field of vaccines for the prevention or treatment of congenital infection of cytomegalovirus, capable of addressing the effects of transplacental infection No hints were given, and the combination use could not be accurately shown effect, the effect of the infection defense capability has not yet been confirmed, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0101] [Materials / Methods]
[0102]
[0103] For evaluation using a guinea pig transplacental infection model system, guinea pig cytomegalovirus (GPCMV) showing infectivity to guinea pigs was used. Since the recombinant GPCMV gB protein sometimes contains aggregates, a modified GPCMV gB protein that does not contain aggregates and has improved properties was produced.
[0104] Artificially synthesized the gene encoding gB (SEQ ID NO. 15) with a leader sequence added to the ectodomain (1-656aa) of gB derived from GPCMV 22122 strain, and amino acid mutations were introduced to improve the traits, and cloned into pCAGGS1-dhfr-neo (Patent Document 3). It is designed to have a His-tag added to the C-terminus of gB. For expression, the Expi293 expression system (Life Technologies Ltd.) was used. The expression plasmid was transfected into the cells, and the cultured supernatant for 4 to 6 days was recovered. From the culture supernatant containing GPCMVgB, it was purified usin...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


